Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest

• Main Authors: Lisa Schaeffer (Author), Nesrine Ben-Anaya (Author), Christina Sorbe (Author), Stephan Jeff Rustenbach (Author), Ulrich Mrowietz (Author), Matthias Augustin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with pso...